Specifications
| Product Cat#: |
AB-06-5071 |
| Product type: |
Primary antibody |
| Antigen: |
Gasdermin D |
| Immunogen: |
Recombinant protein within human Gasdermin D aa 100-300. |
| Species immunized: |
Rabbit |
| Isotype: |
IgG |
| Applications: |
Western Blot (1:500-1:2000); Immunocytochemistry (1:50-1:100); Immunohistochemistry-Paraffin (1:50-200); Flow Cytometry (1:50-1:100) |
| Reactivity: |
Human, Mouse, Rat |
| Clonality (clone number): |
Polyclonal |
| Form: |
Liquid |
| Buffer: |
1*PBS buffer (pH 7.4), 0.2% BSA, 50% glycerol, 0.05% NaN3. |
| Concentration: |
1 mg/ml |
| Purity: |
Immunogen affinity purified |
| Storage: |
Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: |
1810036L03Rik antibody |
|
DF 5L antibody |
|
DF5L antibody |
|
DFNA 5L antibody |
|
DFNA5L antibody |
|
FKSG 10 antibody |
|
FKSG10 antibody |
|
FLJ12150 antibody |
|
Gasdermin antibody |
|
Gasdermin D antibody |
|
Gasdermin domain containing 1 antibody |
|
Gasdermin domain containing protein 1 antibody |
|
Gasdermin domain-containing protein 1 antibody |
|
Gasdermin-D antibody |
|
GasderminD antibody |
|
GSDMD antibody |
|
GSDMD_HUMAN antibody |
|
GSDMDC 1 antibody |
|
GSDMDC1 antibody |
Gasdermin-D, N-terminal
Promotes pyroptosis in response to microbial infection and danger signals (PubMed:26375003, PubMed:26375259, PubMed:27418190, PubMed:28392147, PubMed:32820063).
Produced by the cleavage of gasdermin-D by inflammatory caspases CASP1, CASP4 or CASP5 in response to canonical, as well as non-canonical (such as cytosolic LPS) inflammasome activators (PubMed:26375003, PubMed:26375259, PubMed:27418190).
After cleavage, moves to the plasma membrane where it strongly binds to inner leaflet lipids, including monophosphorylated phosphatidylinositols, such as phosphatidylinositol 4-phosphate, bisphosphorylated phosphatidylinositols, such as phosphatidylinositol (4,5)-bisphosphate, as well as phosphatidylinositol (3,4,5)-bisphosphate, and more weakly to phosphatidic acid and phosphatidylserine (PubMed:27281216, PubMed:29898893).
Homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the release of mature interleukin-1 (IL1B and IL18) and triggering pyroptosis (PubMed:27418190, PubMed:27281216, PubMed:29898893, PubMed:33883744).
Gasdermin pores also allow the release of mature caspase-7 (CASP7) (By similarity).
Exhibits bactericidal activity (PubMed:27281216).
Gasdermin-D, N-terminal released from pyroptotic cells into the extracellular milieu rapidly binds to and kills both Gram-negative and Gram-positive bacteria, without harming neighboring mammalian cells, as it does not disrupt the plasma membrane from the outside due to lipid-binding specificity (PubMed:27281216).
Under cell culture conditions, also active against intracellular bacteria, such as Listeria monocytogenes (By similarity).
Also active in response to MAP3K7/TAK1 inactivation by Yersinia toxin YopJ, which triggers cleavage by CASP8 and subsequent activation (By similarity).
Strongly binds to bacterial and mitochondrial lipids, including cardiolipin (PubMed:27281216).
Does not bind to unphosphorylated phosphatidylinositol, phosphatidylethanolamine nor phosphatidylcholine (PubMed:27281216).
Gasdermin-D
Precursor of a pore-forming protein that plays a key role in host defense against pathogen infection and danger signals (PubMed:26375003, PubMed:26375259, PubMed:27281216).
This form constitutes the precursor of the pore-forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-D, N-terminal) binds to membranes and forms pores, triggering pyroptosis (PubMed:26375003, PubMed:26375259, PubMed:27281216).
Provider
Erpantech Laboratory
